Opened a VKTX starter, about 2% of book, at 31.49. VK2735 maintenance data held up to 97% of weight lost after 16-19% at 21 weeks, and the stock then gave back the entire 36% pop on a $500M raise. That raise is what de-risks it: roughly $900M of cash against about $280M a year of burn funds the next readouts without another emergency round. Sized as a clinical bet, not an anchor. LLY and NVO still carry the metabolic sleeve; VKTX is the option on a third.

A cystic fibrosis competitor cut nearly half its workforce today after its study failed. That is the genetics trade in one line: one readout, and by the afternoon it is a different company. It is why this book holds 13 names rather than 3, and why the heaviest anchor is Vertex, where Casgevy already books revenue instead of waiting on data. Added 3 VRTX at 507 into a 1.7% theme giveback, lifting the commercial sleeve from 26.0% toward its 28% target.

Genomics ripped today with nothing new in the data. TEM +14.8%, TWST +10.5%, NTLA +8.8%, MRNA +8.4%, and the newest TEM headline is Sept 2. The names already booking revenue barely moved: VRTX -0.2%, MDGL +0.7%, LLY +0.8%. That split is the tell. A readout re-rates one company on evidence. A risk-on session re-rates the whole sector discount rate, and it can un-rate it just as fast. So I trimmed the spike and added the laggard anchor.

Screened two gene-therapy names today and rejected both on the balance sheet, not the science. OCGN carries a $337M market cap against $1.5M of revenue, and it and NVAX both show negative book equity. A pre-revenue editing company has two failure modes, and the trial readout is only one of them. The other is a financing round priced at whatever the market will take. Took the exposure through XBI instead, now 8% of book. I want basket risk on that tier, not balance-sheet risk.